The present invention disclosed a novel (4,8-bis(5-(trimethylstannyl)thiophen-2-yl)benzo[1,2-b:4,5-b]dithiophene-2,6-diyl)bis(trimethylstannane) compound, its preparation and use for the synthesis of polymers, which is used to build devices for capacitor and solar applications. The present invention further discloses to an improved process for the synthesis of DTBDT having improved yields.

A metal-containing onium salt compound suitable for use as a photodegradable base of a resist composition and a resist composition using the metal-containing onium salt compound are provided, the resist composition having excellent sensitivity to ionizing radiation such as extreme ultraviolet (EUV), excellent resolution and focal depth in lithography, and can reduce line width roughness (LWR) in a fine pattern. The onium salt compound including a specific metal is used as the photodegradable base.

The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. ##STR00001##
(In the formula, each of A and Z independently represents CO, SO or SO.sub.2; each of X and Y independently represents S or O; each of R.sup.1-R.sup.4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R.sup.5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.

The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.

Described herein are complexes comprising a cationic antibacterial agent and a metal salt; oral care compositions comprising same; along with methods of making and using these complexes and compositions.

Substituted cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes as active substances against abiotic plant stress Cyanocycloalkylpenta-2,4-dienes, cyanocycloalkylpent-2-en-4-ynes, cyanoheterocyclylpenta-2,4-dienes and cyanoheterocyclylpent-2-en-4-ynes of the general formula (I) or salts thereof ##STR00001## where [X-Y], Q, R.sup.1, R.sup.2, A.sup.1, A.sup.2, V, W, m and n are each as defined in the description, to processes for preparation thereof and to the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

A metal tin cyclized perylene diimide derivative, having a structure formula of: ##STR00001##
where R.sub.1 and R.sub.2 are each independently selected from a hydrogen atom or a group containing or not containing a substituent. The group containing or not containing a substituent is an alkyl having between 1 and 60 carbon atoms, an alkoxy having between 1 and 60 carbon atoms, a cycloalkyl having between 3 and 60 carbon atoms, an aryl having between 5 and 60 atoms, an alkylaryl having between 1 and 60 carbon atoms, an alkylheteroaryl having between 1 and 60 carbon atoms, an alkylheterocyclyl having between 1 and 60 carbon atoms, an alkyleneoxyalkyl having between 1 and 60 carbon atoms, an alkyleneoxyaryl having between 1 and 60 carbon atoms, an alkyleneoxyheteroaryl having between 1 and 60 carbon atoms, or an alkyleneoxyheterocyclyl having between 1 and 60 carbon atoms.

A novel method and system for using certain tin compounds as dopant sources for ion implantation are provided. A suitable tin-containing dopant source material is selected based on certain attributes. Some of these attributes include stability at room temperature; sufficient vapor pressure to be delivered from its source supply to an ion chamber and, the ability to produce a suitable beam current for ion implantation to achieve the required implant Sn dosage.

The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II

##STR00001##

or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

Colloidal perovskite nanoplatelets can provide a material platform, with tunability extending from the deep UV, across the visible, into the near-IR. The high degree of spectral tunability can be achieved through variation of the cation, metal, and halide composition as well as nanoplatelet thickness.